Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

FBDIX Franklin Biotechnology Discovery A

  • Fund
  • FBDIX
  • Price as of: Jun 14, 2019
  • $138.55 - $1.43 - 1.02%
  • Category
  • Health & Biotech Equities

FBDIX - Profile

Vitals

  • YTD Return 13.2%
  • 3 Yr Annualized Return 2.9%
  • 5 Yr Annualized Return -0.1%
  • Net Assets $1.09 B
  • Holdings in Top 10 44.9%

52 WEEK LOW AND HIGH

$138.55
$112.89
$165.77

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.05%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 26.95%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$1,000

IRA

$250

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 13.2%
  • 3 Yr Annualized Total Return 5.3%
  • 5 Yr Annualized Total Return 3.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.53%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Franklin Biotechnology Discovery Fund
  • Fund Family Name Franklin Templeton Investments
  • Inception Date Sep 15, 1997
  • Shares Outstanding 6577357
  • Share Class A
  • Currency USD
  • Domiciled Country United States
  • Manager Evan S. McCulloch

Fund Description

The Franklin Biotechnology Discovery Fund Class A (FBDIX) is an actively managed fund that specializes in the health care sector. FBDIX specifically targets those biotech companies engaged in new drug development and marketing. This includes firms in genomics research, genetic engineering and gene expression therapy. Managers use a bottom-up, fundamental approach to picking biotech stocks for FBDIX’s assets and lean heavily on stocks with competitive profiles and large market opportunities for their drugs.

Fees for FBDIX are considered low. However, given its specialized nature, the fund is only suitable as a satellite position. The fund is internally managed by Franklin Advisers.

FBDIX - Performance

Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 13.2% N/A N/A N/A
1 Yr -11.4% N/A N/A N/A
3 Yr 2.9%* N/A N/A N/A
5 Yr -0.1%* N/A N/A N/A
10 Yr 10.4%* N/A N/A N/A

* Annualized


Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2018 -18.6% N/A N/A N/A
2017 16.0% N/A N/A N/A
2016 -20.7% N/A N/A N/A
2015 -3.0% N/A N/A N/A
2014 28.6% N/A N/A N/A

Total Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 13.2% N/A N/A N/A
1 Yr -11.4% N/A N/A N/A
3 Yr 5.3%* N/A N/A N/A
5 Yr 3.9%* N/A N/A N/A
10 Yr 14.9%* N/A N/A N/A

* Annualized


Total Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2018 -18.6% N/A N/A N/A
2017 18.8% N/A N/A N/A
2016 -17.1% N/A N/A N/A
2015 5.7% N/A N/A N/A
2014 33.8% N/A N/A N/A

NAV & Total Return History

FBDIX - Holdings

Concentration Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Assets 1.09 B N/A N/A N/A
Number of Holdings 88 N/A N/A N/A
Net Assets in Top 10 508 M N/A N/A N/A
Weighting of Top 10 44.85% N/A N/A N/A

Top 10 Holdings

  1. Alexion Pharmaceuticals Inc 7.20%

  2. Vertex Pharmaceuticals Inc 5.31%

  3. Array BioPharma Inc 5.27%

  4. Illumina Inc 5.07%

  5. Biogen Inc 4.09%

  6. GW Pharmaceuticals PLC ADR 3.90%

  7. Regeneron Pharmaceuticals Inc 3.79%

  8. Gilead Sciences Inc 3.59%

  9. Biomarin Pharmaceutical Inc 3.34%

  10. Amgen Inc 3.30%


Asset Allocation

Weighting Return Low Return High FBDIX % Rank
Stocks
97.50% N/A N/A N/A
Cash
2.33% N/A N/A N/A
Other
0.17% N/A N/A N/A
Preferred Stocks
0.00% N/A N/A N/A
Convertible Bonds
0.00% N/A N/A N/A
Bonds
0.00% N/A N/A N/A

Stock Sector Breakdown

Weighting Return Low Return High FBDIX % Rank
Healthcare
97.41% N/A N/A N/A
Energy
0.09% N/A N/A N/A
Utilities
0.00% N/A N/A N/A
Technology
0.00% N/A N/A N/A
Real Estate
0.00% N/A N/A N/A
Industrials
0.00% N/A N/A N/A
Financial Services
0.00% N/A N/A N/A
Communication Services
0.00% N/A N/A N/A
Consumer Defense
0.00% N/A N/A N/A
Consumer Cyclical
0.00% N/A N/A N/A
Basic Materials
0.00% N/A N/A N/A

Stock Geographic Breakdown

Weighting Return Low Return High FBDIX % Rank
US
89.78% N/A N/A N/A
Non US
7.72% N/A N/A N/A

FBDIX - Expenses

Operational Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.05% N/A N/A N/A
Management Fee 0.58% N/A N/A N/A
12b-1 Fee 0.25% N/A N/A N/A
Administrative Fee 0.15% N/A N/A N/A

Sales Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% N/A N/A N/A
Deferred Load N/A N/A N/A N/A

Trading Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A N/A N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 26.95% N/A N/A N/A

FBDIX - Distributions

Dividend Yield Analysis

FBDIX Category Low Category High FBDIX % Rank
Dividend Yield 0.00% N/A N/A N/A

Dividend Distribution Analysis

FBDIX Category Low Category High Category Mode
Dividend Distribution Frequency Annually

Dividend Payout History


Net Income Ratio Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Income Ratio -0.53% N/A N/A N/A

Capital Gain Distribution Analysis

FBDIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually

FBDIX - Managers

Evan S. McCulloch

Manager

Start Date

Tenure

Tenure Rank

Sep 15, 1997

21.72

21.7%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.


Steven Kornfeld

Manager

Start Date

Tenure

Tenure Rank

Sep 15, 2015

3.71

3.7%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.


Wendy Lam

Manager

Start Date

Tenure

Tenure Rank

Sep 01, 2018

0.75

0.8%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.


Tenure Analysis

Category Low

N/A

Category High

N/A

Category Average

N/A

Category Mode

N/A